“There is no admission of liability, and we remain steadfast that the claims raised in the litigation contradict years of scientific data and the U.S. Food and Drug Administration’s repeated confirmation of Xarelto’s safety and efficacy.” These are the words a Janssen Pharmaceuticals spokeswoman emailed the Associated Press in an effort to take the sting out of the fact that the company, along with Bayer, had just read more.... -->
continue reading...
The results of AstraZeneca’s recent trials for its blood-thinning drug Brilinta show a decreased risk of post–heart attack heart problems but an increased risk of major bleeding after using the drug. The pharmaceutical company’s large-scale PEGASUS-TIMI 54 trial included 21,000 patients who had suffered at least one heart attack in the past three years. Patients received either a high dose of Brilinta, a low dose of Brilinta, or a placebo drug. All patients ...
Doctor says blood thinner carries risks
Posted March 2, 2013 in Pradaxa Internal Bleeding | Product News and Recalls
In a column in the Spokesman-Review out of Washington, Dr. Anthony L. Komaroff, M.D., answers a letter-writer’s question about the blood-thinner Pradaxa.
The letter-writer says his wife has atrial fibrillation, and her medication was recently changed from warfarin to Pradaxa. He wants to know if she’s right in claiming that the medicine is just as effective, although it requires fewer tests.
Komaroff writes that technically, Pradaxa is just as effective in preventing blood clots. But Pradaxa presents some risks that warfarin, the ...
continue reading...Blood thinner approval has competitors ‘on their toes’
Posted February 12, 2013 in Health | Pradaxa Internal Bleeding | Product Liability | Product News and Recalls
A report on the blog FiercePharma says the approval of blood thinner Eliquis in Europe has the manufacturers of competing medications “on their toes.”
Eliquis, from Pfizer and Bristol-Myers Squibb, was developed as an alternative to warfarin, which for decades has been the standard treatment for blood clot prevention.
But according to FiercePharma, warfarin “comes with a host of dosage-tweaking rules, plus interactions with alcohol and food, so it is difficult ...
continue reading...FDA approves new blood thinner
Posted January 10, 2013 in Health | Legal Issues | Pradaxa Internal Bleeding | Product Liability | Product News and Recalls
The U.S. Food and Drug Administration has approved a new blood thinner manufactured by Pfizer Inc. and Bristol-Myers Squibb. A Bloomberg report describes Eliquis as a “potential blockbuster heart drug.”
The Food and Drug Administration cleared Eliquis for the prevention of blood clots that develop in patients with the heart rhythm disorder atrial fibrillation, after the manufacturers failed in two previous efforts to win approval for the drug.
It’s among a ...
continue reading...Blood thinner approved in Japan
Posted January 9, 2013 in Health | Legal Issues | Pradaxa Internal Bleeding | Product Liability | Product News and Recalls
Regulators in Japan have approved the blood thinner Eliquis, the Japan Daily Times reports.
Eliquis is the brand name for apixaban, manufactured by Bristol-Myers Squibb Co and Pfizer Inc. It’s among a new class of blood thinners meant to replace decades-old warfarin, which is effective but can be difficult to use because it requires dietary restrictions and frequent testing.
Pharmaceutical companies have been looking to warfarin alternatives as potentially profitable areas ...
continue reading...
